Header

Header

Header

Accelerate Your Therapeutic Pipeline Power by OligoTX™

Therapeutic Oligonucleotide Service from Bio-Synthesis

45+ Years of Expertise Research to preclinical Support ISO 9001:2015 / ISO 13485:2016 GLP/cGMP-Aligned U.S Facilities in Texas Confidential & IP-Protected

Overview

Therapeutic oligonucleotides are short, synthetic nucleic acid molecules used to regulate gene expression for research, preclinical, and drug development applications. Common formats include siRNA, antisense oligonucleotides (ASOs), splice-switching oligonucleotides (SSOs), and other modified RNA or DNA constructs.

Bio-Synthesis provides custom oligonucleotide synthesis, chemical modification, bioconjugation, purification, scale-up, and analytical QC support for RNA-targeted and oligonucleotide-based programs.

therapeutic oligonucleotide development workflow showing siRNA and ASO design chemical modification conjugation delivery and gene silencing process

Therapeutic oligonucleotide workflow: design, modification, conjugation, delivery, and biological activity.

Modalities

siRNA / ASO

Plus SSO and modified oligos

Chemistry

Modified

2′-OMe, 2′-F, PS, LNA

Conjugation

Targeted

GalNAc, lipid, peptide, ligand

QC

HPLC / MS

Purity and identity support

Development Journey: RUO to cGMP Support

Bio-Synthesis specializes in custom oligonucleotide synthesis with rapid turnaround, flexible scale-up, and full-spectrum support from RUO to cGMP. Our facility produces microgram to multi-gram quantities to match your evolving development needs.

Scale

Microgram to multi-gram synthesis capabilities

Speed

Rapid turnaround for custom oligo programs

Flexibility

Client-centric support from feasibility to development

Quality

Manufacturing under ISO 13485-certified quality standards

oligonucleotide therapeutic development journey from R and D through analytical development preclinical clinical RUO and cGMP support

Compact development pathway from R&D and analytical development through preclinical and clinical-stage support.

From early feasibility through clinical development, Bio-Synthesis supports therapeutic oligonucleotide programs with reliable synthesis, precise modification, scalable production, and quality-focused documentation.

Therapeutic Oligonucleotide Capabilities

Custom Synthesis

Custom synthesis support for therapeutic and preclinical oligonucleotide programs, including RNA, DNA, and modified oligo constructs.

  • Custom siRNA and ASO synthesis
  • Splice-switching oligos
  • Modified RNA and DNA constructs

Chemical Modifications

Modification options help improve stability, nuclease resistance, binding behavior, and application-specific performance.

  • 2′-OMe, 2′-F, LNA
  • Phosphorothioate linkages
  • Terminal protection and specialty linkers

Conjugation Support

Bioconjugation options support targeting, uptake, tracking, and delivery-oriented development workflows.

  • GalNAc conjugation
  • Lipid and peptide conjugates
  • Ligand, linker, and reactive-handle chemistry

Supported Therapeutic Oligonucleotide Modalities

This page provides a high-level overview of common oligonucleotide modalities supported for therapeutic and preclinical applications.

Modality General role Common application
siRNA RNA interference and target gene knockdown Functional genomics, target validation, RNAi therapeutic programs
ASO RNA modulation through RNase H activity, steric blocking, or other mechanisms RNA-targeted research, gene regulation, therapeutic development
SSO Splice modulation and exon inclusion or exclusion strategies Splicing research and genetic disease programs
Modified RNA / DNA Oligos Custom oligos with chemical modifications or conjugates Research, preclinical development, assay, imaging, and delivery workflows

Delivery and Conjugation Options

GalNAc Conjugation

GalNAc conjugation is commonly used for liver-targeted oligonucleotide delivery strategies.

Lipid and LNP Workflows

Lipid conjugates and lipid nanoparticle workflows support delivery-oriented oligonucleotide development.

Peptide and Ligand Conjugates

Peptides, ligands, and reactive handles can support targeted delivery, uptake studies, and custom conjugate design.

Manufacturing, Purification, and Quality Support

Manufacturing Support

Programs can be configured for research, preclinical, and development-stage needs with appropriate scale, purification, and documentation.

  • Research to preclinical support
  • Scale-up planning
  • Custom documentation on request

Analytical QC

Analytical support can include purity, identity, and application-specific quality testing depending on the program scope.

  • HPLC / UPLC purity analysis
  • LC-MS or mass confirmation
  • Quantitation and optional testing

End-to-End Quality & Compliance You Can Trust

  • ISO 13485-certified quality system
  • GLP-aligned manufacturing processes
  • Comprehensive analytical QC documentation
  • Full traceability from raw materials to final product
  • Open-door policy for onsite audits
  • Built for precision, traceability, and regulatory confidence

Reliable from Research to Development

Bio-Synthesis delivers consistent quality across every stage of your oligonucleotide program — from early research through development and scale-up.

Our quality-driven processes support reproducibility, regulatory alignment, documentation, and transparency, giving you confidence in every batch produced.

FAQ

What therapeutic oligonucleotide services are available?

Services include custom synthesis, chemical modification, bioconjugation, purification, scale-up, and analytical QC support for therapeutic and preclinical oligonucleotide programs.

What oligonucleotide types are supported?

Supported modalities include siRNA, ASO, splice-switching oligos, modified RNA constructs, modified DNA constructs, and conjugated oligonucleotides.

Can oligos be modified or conjugated?

Yes. Modification and conjugation options include 2′-OMe, 2′-F, phosphorothioate, LNA, GalNAc, lipid, peptide, ligand, linker, and reactive-handle chemistry.

Do you support RUO to cGMP development?

Yes. Programs can be supported from early RUO feasibility through development and cGMP-oriented manufacturing support, depending on oligo type, scale, documentation, QC, and project requirements.

What information helps with quoting?

Useful information includes oligo type, sequence or target, modification needs, conjugation requirements, scale, purification, QC needs, and intended application.

Discuss Your Therapeutic Oligonucleotide Program

For the fastest response, share the oligo modality, sequence or target, modification and conjugation needs, desired scale, purification requirements, QC expectations, and intended application.

Useful Details to Include

  • Oligo modality: siRNA, ASO, SSO, RNA, or DNA
  • Sequence, target gene, or project goal
  • Modification, conjugation, scale, and QC needs

Contact

Why Choose Bio-Synthesis

Trusted by biotech leaders worldwide for over 45+ years of delivering high quality, fast and scalable synthetic biology solutions.